HC Wainwright Cuts Tyra Biosciences (NASDAQ:TYRA) Price Target to $29.00

Tyra Biosciences (NASDAQ:TYRA) had its price target cut by HC Wainwright from $30.00 to $29.00 in a research note released on Tuesday, MarketBeat Ratings reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Tyra Biosciences’ Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($2.60) EPS, Q1 2027 earnings at ($0.56) EPS, Q2 2027 earnings at ($0.57) EPS, Q3 2027 earnings at ($0.57) EPS, Q4 2027 earnings at ($0.58) EPS and FY2027 earnings at ($2.27) EPS.

Several other research analysts have also weighed in on TYRA. Bank of America increased their price objective on shares of Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Tyra Biosciences in a research note on Thursday, September 10th. JonesTrading began coverage on shares of Tyra Biosciences in a research note on Wednesday, June 17th. They set a “buy” rating and a $56.00 price objective for the company. Jefferies Financial Group restated a “buy” rating and set a $42.00 price objective on shares of Tyra Biosciences in a report on Wednesday, August 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $46.89.

Tyra Biosciences Stock Down 3.5%

TYRA stock opened at $22.41 on Tuesday. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -9.34 and a beta of 0.73. Tyra Biosciences has a 52-week low of $12.40 and a 52-week high of $40.65. The stock’s fifty day simple moving average is $27.01 and its 200-day simple moving average is $31.24.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). As a group, analysts anticipate that Tyra Biosciences will post -2.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tyra Biosciences

Several hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC boosted its holdings in Tyra Biosciences by 32.5% in the 1st quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company’s stock worth $148,867,000 after acquiring an additional 955,147 shares during the period. Jupiter Topco LLC acquired a new stake in Tyra Biosciences in the second quarter valued at approximately $139,161,000. BlackRock Inc. purchased a new stake in shares of Tyra Biosciences during the second quarter valued at approximately $96,841,000. 5AM Venture Management LLC purchased a new stake in shares of Tyra Biosciences during the second quarter valued at approximately $32,875,778. Finally, Jennison Associates LLC acquired a new position in shares of Tyra Biosciences during the first quarter worth $24,222,000. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

More Tyra Biosciences News

Here are the key news stories impacting Tyra Biosciences this week:

• Positive Sentiment: HC Wainwright improved its forecasts: The firm raised its FY2026 EPS estimate to a loss of $2.60 from $2.86 and its FY2027 estimate to a loss of $2.27 from $3.20. Quarterly estimates for Q4 2026 and every quarter of 2027 were also raised, suggesting expectations for narrower losses and improving operating performance.
• Positive Sentiment: Buy rating and target remain intact: HC Wainwright reiterated its Buy rating and $29 price objective. That target is above the stock’s recently reported trading level, offering potential upside if the company meets the improved forecasts.
• Neutral Sentiment: Short-interest data shows little measurable bearish positioning: Reported short interest as of September 24 was 0 shares, with a 0.0-day short-interest ratio based on average volume of roughly 1.74 million shares. While the report describes a large increase, the stated figures indicate no meaningful short-selling pressure; investors should treat the data cautiously because the figures appear inconsistent.
• Negative Sentiment: Tyra remains unprofitable: The revised projections still anticipate losses, including a consensus loss of $2.73 per share for the current year. The company’s continued dependence on future clinical and development progress means valuation remains sensitive to execution, funding needs and trial-related news.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for diseases with limited treatment options. The company uses its proprietary SNÅP platform to design small-molecule therapies intended to selectively target disease-driving genetic alterations while addressing resistance mechanisms that can reduce the effectiveness of existing treatments.

Tyra’s lead programs are directed at fibroblast growth factor receptor (FGFR) biology. TYRA-300 is an oral, selective FGFR3 inhibitor being developed for conditions including FGFR3-altered urothelial cancer and achondroplasia, a genetic skeletal disorder.